Rabbit Polyclonal LILRA3 antibody. Suitable for WB, IHC-P and reacts with Human samples. Immunogen corresponding to Recombinant Fragment Protein within Human LILRA3 aa 200-350.
View Alternative Names
CD85e, ILT6, LIR4, LILRA3, Leukocyte immunoglobulin-like receptor subfamily A member 3, CD85 antigen-like family member E, Immunoglobulin-like transcript 6, Leukocyte immunoglobulin-like receptor 4, Monocyte inhibitory receptor HM43/HM31, ILT-6, LIR-4
- IHC-P
Supplier Data
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-LILRA3 antibody (AB235108)
Paraffin-embedded human lung tissue stained for LILRA3 using ab235108 at 1/300 dilution in immunohistochemical analysis.
After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum for 30 minutes at room temperature. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized tissue using an HRP conjugated SP system.
- WB
Supplier Data
Western blot - Anti-LILRA3 antibody (AB235108)
All lanes:
Western blot - Anti-LILRA3 antibody (ab235108) at 1/500 dilution
Lane 1:
A549 (human lung carcinoma cell line) whole cell lysate
Lane 2:
Jurkat (human T cell leukemia cell line from peripheral blood) whole cell lysate
Secondary
All lanes:
Goat polyclonal to rabbit IgG at 1/50000 dilution
Predicted band size: 47 kDa
false
Reactivity data
Properties and storage information
Form
Purification technique
Purification notes
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
LILRA3 modulates immune responses by binding to unknown ligands. It does not associate with any known receptor complex because it does not possess a transmembrane or cytoplasmic domain. LILRA3 may act as a natural antagonist to other LILR receptors by interfering with their ligand interactions. This antagonism helps regulate the functions of the innate and adaptive immune responses by competing with membrane-bound LILR forms for binding with common ligands.
Pathways
LILRA3 influences the pathways involved in immune regulation including the modulation of cytokine production. It has been linked to pathways associated with the inhibition of inflammation intersecting with receptors like LILRA2 and LILRB1 which are also part of the LILR family. These interactions are essential in balancing immune responses possibly by inhibiting excessive activation that could lead to inflammation or autoimmunity.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com